Search

Zai Lab Ltd ADR

Suletud

SektorTervishoid

26.92 1.66

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

26.22

Max

27.1

Põhinäitajad

By Trading Economics

Sissetulek

191K

-51M

Müük

6.7M

106M

Aktsiakasum

-0.46

Kasumimarginaal

-47.808

Töötajad

1,784

EBITDA

-2.1M

-46M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+48.53% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

5. nov 2026

Turustatistika

By TradingEconomics

Turukapital

805M

2.9B

Eelmine avamishind

25.26

Eelmine sulgemishind

26.92

Uudiste sentiment

By Acuity

34%

66%

91 / 339 Pingereas Healthcare

Zai Lab Ltd ADR Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. sept 2026, 23:56 UTC

News

Missouri American Water acquired Neosho's water systems for $34.5 million, adding 5,400 customers. Shares of American Water Works traded higher in after-market hours.

3. sept 2026, 23:56 UTC

News
Correlated Moves

Paychex receives a buy rating on strong revenue growth and strategic AI integration. After-market trading has shown little change since Thursday's close.

3. sept 2026, 23:56 UTC

News

Jefferies initiated coverage on Nexgen Energy with a Buy rating and a C$21 price target. Shares moved higher in after-market hours.

3. sept 2026, 23:51 UTC

News

Regeneron Pharmaceuticals faces a class action lawsuit over misleading statements about its Phase III Fianlimab-Libtayo Study, with shares trading lower in after-market hours.

3. sept 2026, 23:51 UTC

News
Social Media

Dutch Bros Inc filed a mixed securities shelf registration, enabling potential issuance of various securities. Shares are trading higher in after-market hours.

3. sept 2026, 23:51 UTC

News
Social Media

Tesla Inc. shares are lower in after-market trading following the invite-only launch event for its Cybercab in Austin, as details remain restricted.

3. sept 2026, 23:46 UTC

News

Weyerhaeuser Co remains about 4.95% below its 20-day moving average. Shares were roughly flat in after-market hours following a price target cut to $28.

3. sept 2026, 23:46 UTC

News
Social Media

Hewlett Packard Enterprise shares are lower in after-market trading, despite strong networking revenue guidance and broader market gains ahead of employment data.

3. sept 2026, 23:41 UTC

News

JP Morgan upgrades CPRT to Overweight, raises target to $40 after-market.

3. sept 2026, 23:41 UTC

News

Johnson & Johnson's shares are lower in after-market trading following FDA approval of IMAAVY and a jury verdict in a talc case.

3. sept 2026, 23:36 UTC

News

Ulta Beauty will participate in a Fireside Chat at the Barclays Global Consumer Conference on September 10, 2026. Shares are higher in after-market trading.

3. sept 2026, 23:31 UTC

News

Honeywell International Inc shares are lower in after-hours trading, despite broader market gains. The stock is near the lower end of its one-month range.

3. sept 2026, 23:26 UTC

News

Jefferies maintained a Buy rating on Five Below and raised its price target to $420. Shares are trading higher in after-market hours following the updates.

3. sept 2026, 23:21 UTC

News
Social Media

Meta Platforms Inc. shares are higher in after-market hours, supported by a Buy rating from Bank of America with a price target of $810.

3. sept 2026, 23:21 UTC

News

Thermo Fisher Scientific shares are lower in after-market hours despite CLSA initiating coverage with an Outperform rating and a $748 price target.

3. sept 2026, 23:11 UTC

News

Ethereum is trading higher during Thursday's session, remaining above its 20-day moving average and near the upper end of its one-month range.

3. sept 2026, 23:11 UTC

News

Ethereum is trading higher today, remaining above its 20-day moving average and near the upper end of its one-month trading range.

3. sept 2026, 23:05 UTC

News

USD/HKD trades roughly flat amid stable market activity. An increase in USDE supply to $4.26 billion may influence dynamics but has not impacted prices today.

3. sept 2026, 23:05 UTC

News

WEX Inc. shares decline in after-market hours despite announcing an integration with Driivz Ltd. for electric vehicle charging solutions, with a fair value of $187.30.

3. sept 2026, 23:05 UTC

Correlated Moves
News

Elastic NV plans to integrate OpenAI GPT cyber models into its Elastic Security platform, enhancing security capabilities. Shares are trading roughly flat in after-market hours.

3. sept 2026, 23:05 UTC

Macro Event
Correlated Moves
News

The USD/PLN exchange rate is declining amid mixed U.S. jobless claims data, with initial claims rising slightly above expectations.

3. sept 2026, 23:02 UTC

News
Social Media

Lululemon Athletica reported second-quarter revenue of $2.42 billion, below estimates. The stock fell sharply in after-market hours, reaching its lowest level since May 2018.

3. sept 2026, 23:02 UTC

News
Correlated Moves
Social Media

DocuSign shares rise in after-market trading following strong fiscal Q2 results and raised revenue guidance, despite earlier pulling back from a session high.

3. sept 2026, 23:01 UTC

News

PulteGroup Inc shares are higher in after-market hours following a Buy rating from StoneX analyst Michael, who set a price target of $148.00.

3. sept 2026, 23:01 UTC

News

eGain Corp shares are lower in after-market trading following disappointing fiscal 2027 guidance, despite reporting revenue and adjusted EPS that exceeded estimates.

3. sept 2026, 23:01 UTC

News

Concrete Pumping Holdings reported strong Q3 results, raising revenue guidance and announcing a quarterly dividend, driving shares higher in after-market trading.

3. sept 2026, 23:01 UTC

News
Social Media
Event

UiPath Inc shares declined in after-market hours despite reporting second-quarter revenue of $410 million and raising its fiscal year 2027 outlook.

3. sept 2026, 23:01 UTC

News
Event

Oxford Industries reports second-quarter sales of $394 million and lowers full-year adjusted EPS guidance to $1.60-$2.00, leading shares lower in after-market hours.

3. sept 2026, 23:01 UTC

News
Social Media

Strategy Inc shares declined after hours, retracing from earlier gains amid social media discussions and news from Iran affecting sentiment.

3. sept 2026, 23:01 UTC

News
Event
Social Media

Smith & Wesson Brands reported strong Q1 results, with net sales of $112.6 million and adjusted EPS of $0.06, boosting shares in after-market trading.

Võrdlus sarnastega

Hinnamuutus

Zai Lab Ltd ADR Prognoos

Hinnasiht

By TipRanks

48.53% tõus

12 kuu keskmine prognoos

Keskmine 39.33 USD  48.53%

Kõrge 45 USD

Madal 36 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Zai Lab Ltd ADR 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

3

Osta

0

Hoia

0

Müü

Sentiment

By Acuity

91 / 339 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat